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production pressures. Federal government support 
step forward in the control of a major infective diseas
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Ag
allA he end of 2006, the Australian Ministers for Health andriculture announced funding for an upgraded facility toow CSL Limited to recommence production of the Q
fever vaccine (Q-Vax) and comply with changed biocontainment
regulations.1 Production of the vaccine had ceased at the end of








National Q Fever Management Program, 2001–2003/2004 (http://
www.immunise.health.gov.au/internet/immunise/publishing.nsf/
Content/q-fever-man).
Attempts to control Q fever by vaccination have a long history.2
After the discovery of clinical Q fever and isolation of the causative
organism by Edward Derrick in Queensland in the 1930s, and the
subsequent identification of the isolates (an obligate intracellular
bacterium) by Macfarlane Burnet, the disease emerged as an
important “campaign” infection (Balkan grippe) for armies in the
Mediterranean arena during World War II. At the time, various
vaccine formulations were prepared from the coxiella grown
abundantly in chick embryo yolk sacs, as devised by H R Cox at
the National Institutes of Health/National Institute of Allergy and
Infectious Diseases, Rocky Mountain Laboratory, Montana, USA.
Suspensions of infected yolk sac were inactivated with formalin
and ether (eg, by Smadel and colleagues).2 These were protective
in animals and in human volunteer and challenge trials. But use in
humans produced unpredictable, severe local reactions.
Derrick expressed a common view of these early Q fever
vaccines in his 1964 Elkington Oration: “What of the future; there
is an effective vaccine but it produces unacceptable reactions”.3 His
assessment is still repeated uncritically in the medical literature.
The experience in Australia from 1980 to 2005 with the present
generation of whole-cell vaccines (eg, Q-Vax [CSL Limited]) and a
different vaccination protocol has been quite the reverse. The
contemporary whole-cell, formalin-inactivated Q fever vaccine has
also sometimes been dismissed as “old-fashioned”— ignoring a
protective efficacy of over 95%. In fact, the formulation is appro-
priate for the complex immunopathology of acute Q fever.
Insight into the critical components for an improved whole-cell
vaccine started in Cambridge in the 1950s with Stoker and Fiset’s4
discovery of the antigenic phase variation of Coxiella burnetii.
Concurrent studies, also in Cambridge, by Abinanti and Marmion5
showed that antibody to the Phase I antigen (ie, the lipopolysac-
charide of coxiella cells with a complete set of sugar residues in its
O-chains) was protective in a mouse spleen model of Q fever
infection. On the other hand, protection was not conferred by
antibody to Phase II antigens (ie, from coxiella with a full
complement of proteins, but with genetically driven or other
variations in the level of synthesis of complete lipopolysaccharide
O-chains — recent research reports6,7 give a more detailed expla-
nation of the chemistry of phase variation).
Subsequently, Ormsbee et al8 at Rocky Mountain Laboratory
extended these observations to show that a formalin-inactivated
vaccine made from coxiella predominantly in the Phase I antigenic
state was significantly more protective in a guinea pig model of Q
fever on a weight-for-weight basis than one made from cells
predominantly in Phase II. The latter preparation, and indeed the
earlier vaccines developed by Smadel, probably owed their partial
protective properties to residual Phase I cells in a population of
Phase II variants. The importance of Phase 1 lipopolysaccharide as
a protective immunogen is supported by the finding that a Phase I
Q fever vaccine loses its protective efficacy in mice when treated
with potassium periodate to ablate the sugar residues in the
lipopolysaccharide (unpublished data).
The major host cells for C. burnetii in animals and humans are in
the monocyte–macrophage lineage. The interactions of coxiella
with this key regulatory cell series for the cellular immune system
underlie both the immunopathogenesis of Q fever and the pro-
phylaxis afforded by the vaccine. The coxiella proteins (as pep-
tides) stimulate T-lymphocyte immunity and memory, with the
generation of interferon-γ  and other cytokines that control intra-
cellular replication of coxiella.2 On the other hand, interactions of
coxiella and monocyte–macrophage cells produce mediators that
down-regulate the cellular immune system and the formation of
interferon-γ  by T lymphocytes.9,10 A possible explanation for the
central requirement of the Phase I determinant in a vaccine is that
antibody to it blocks interaction of coxiella and the monocyte–
macrophage cells. Consequently, down-regulation of the cellular
immune system does not occur and coxiella growth is restricted.
A contributory component for vaccine efficacy may be the slow
biodegradability of the small-cell variant of coxiella. This displays
both Phase I lipopolysaccharide and protein antigens, thus provid-
ing continuing antigenic stimulation and protection.
An important step in the development of the current protocol
for vaccination was the finding by Lackman and colleagues2 at
Rocky Mountain Laboratory that adverse reactions to whole-cell
vaccine could be minimised by intradermal skin testing of poten-
tial vaccinees with a dilute vaccine to detect prior cellular immune
sensitisation.
In the early 1980s, 50 years after Derrick’s discovery — and
probably after some 40 000 overt cases of Q fever — Dick
Ormsbee and I asked CSL Limited to make Ormsbee’s highly
purified version2 of Q fever vaccine with its negligible residual yolk
protein. At the time we knew that Hornick, Fiset and colleagues,2
under the auspices of the Commission on Rickettsial Diseases (US
Armed Forces), had vaccinated volunteers with whole-cell vaccine
and challenged them with aerosols of living C. burnetii. Even small
doses (1–10 μg) of vaccine were protective.
Open clinical trials of the Ormsbee-type vaccine (Q-Vax) (pro-
duced by CSL) at a dose of 30 μg as a subcutaneous injection were164 MJA • Volume 186 Number 4 • 19 February 2007
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1980s.2 These established the vaccine’s safety in an industrial
environment in which prior clinical or subclinical infection and
immune sensitisation were common. As in the US volunteer trials,
the vaccine was protective.
A formal “blind” comparison of Q-Vax and influenza virus
vaccine performed at three Queensland abattoirs also showed
complete protection.2
Box 1 shows the practical value of vaccine prophylaxis in a large
abattoir group in Queensland, 1992–2005. Occupationally
acquired, laboratory-proven Q fever is compensable. Compensa-
tion claims — a significant expense for the industry — declined
steadily after the vaccination program started. Box 2 shows the
number of Q fever cases notified to the National Notifiable
Diseases Surveillance System across Australia, 1991–2006. The
yearly totals include Q fever cases both in and outside abattoirs.
Abattoirs across the country gradually took up vaccination from
1993–1994, greatly aided by CSL’s vaccine consultants. During the
period 1994–2000, although the number of Q fever notifications
stabilised at around 500–600 per year, probably reflecting fewer
cases in abattoirs, an unambiguous downward trend in Q fever
notifications for the country as a whole did not occur. This is not
surprising, as it has been apparent since the 1930s that only a
variable proportion of Q fever cases occurs in abattoirs (eg, 68% of
Derrick’s series of 273 cases11).
During the National Q Fever Management Program, state immu-
nisation teams worked intensely to vaccinate abattoir workers, and
rural and other at-risk groups in the population. Evaluation
continues, but Box 2 shows an encouraging and significant decline
in case numbers from 2003 to 2006.
What of the future? Further refinement of existing vaccine
protocols is needed as problems surface from wider use. Efforts to
produce less reactogenic vaccines for use without pretesting are
summarised in Box 3.2 Balanced against the continuing and
substantial Q fever problem in Australia, the current whole-cell
vaccine and protocol are effective, they have been tested in over
150 000 subjects, and prophylaxis for this disease is available now.
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3 Efforts to produce less reactogenic, alternative 
vaccines without the need for pretesting
Extracts of coxiella containing lipopolysaccharides and protein (eg, 
chemovaccine)2 or delipidated coxiella cell residues2 are protective 
in animals. Chemovaccine has been used in Eastern Europe in 
laboratory workers and some industrial groups. It is protective, but 
about as reactogenic as whole-cell vaccine. To establish efficacy, 
duration of protection and reactogenicity (severe adverse incidents 
are rare and idiosyncratic), comparative trials are needed of these 
vaccines versus whole-cell vaccine in larger numbers of subjects.
There is also active research into simpler vaccines of coxiella 
proteins prepared by recombinant DNA methods.12 So far, coxiella 
proteins alone appear not to be protective,13 although a 
recombinant fusion protein given with Freund’s complete adjuvant 
(a potent macrophage activator) protected in a mouse model.14
The quest for a simpler vaccine should continue; whether successful 
or not, it is yielding valuable insights into the immunobiology of Q 
fever. But the three-component nature of the existing vaccine and 
the roles in protection of lipopolysaccharides, macrophages and 
antibody need to be taken into account. ◆MJA • Volume 186 Number 4 • 19 February 2007 165
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The management of upper gastrointestinal symptoms: 
is endoscopy indicated?
Anne E Duggan
Testing for Helicobacter pylori, and acid-suppression therapy are nearly always better strategies
ost patients with upper gastrointestinal symptoms can
be effectively managed without investigation. Recent
long-term follow-up of patients with upper gastrointesti-
nal symptoms shows that most have a benign course.1,2 A recent
follow-up of 300 patients 9 years after investigations showed that
40% were asymptomatic; 70% of these without medication.2 Such
a good outcome is the result of the decline of Helicobacter pylori3
(making peptic ulcer uncommon and gastric cancer rare in the
absence of genetic or ethnic predisposition) and the easy availabil-
ity of effective acid-suppression therapy (making gastro-oesopha-
geal reflux disease easily treatable). For the vast majority of
patients, upper gastrointestinal symptoms are now a dis-ease, not a
disease.
These changes in epidemiology and treatment simplify the
management approach to upper gastrointestinal symptoms (Box).
Gastroscopy now has a low diagnostic yield. A review of 22 studies
investigating dyspepsia found that, overall, findings in 50% of
gastroscopies were normal, 12% revealed reflux oesophagitis, 33%
gastroduodenal ulceration, and 1.2% malignancy.5 International
management guidelines recommend two alternatives to gastro-
scopy:
• empiric acid-suppression therapy; or
• H. pylori testing and treatment.4
Acid-suppression therapy is effective treatment for gastro-
oesophageal reflux disease (GORD), and the “omeprazole test” (a
simple trial of omeprazole [40 mg twice daily for a week])
diagnoses GORD more accurately than endoscopy, and with a
sensitivity of around 80%.6 For population groups with a high
prevalence of H. pylori infection, such as the elderly and some
ethnic groups, H. pylori testing and treatment has advantages. For
younger patients, H. pylori infection is unlikely, as childhood
domestic hygiene has improved.
If a test for H. pylori is positive, treatment provides:
• definitive treatment of peptic ulcer disease;
• no adverse outcome for non-ulcer disease;
• risk reduction for ulcer disease associated with non-steroidal
anti-inflammatory drug (NSAID) treatment; and
Algorithm for the management of uninvestigated 
dyspepsia*
* Adapted from Talley.4
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